RTTNews BiotechCodex · 实盘可交易 · 做多市场:港股▼ 亏 -1.06% · 已结算把握 7/10
北京时间·🕒 发布 11:45:09时区推断·⟳ 抓取 12:00:24·⚡ 决策 08-04 13:48:47 +1h48m·84.4 天前
康宁杰瑞将JSKN016全球权益授权给Pathos AI，获1.25亿美元首付款及最高20.9亿美元里程碑
康宁杰瑞制药-B（09966.HK）获得1.25亿美元不可退还首付款，约9.75亿港元，占当前约75.9亿港元市值约12.9%，对小市值港股Biotech属于可量化现金流重估。
📄 原文RTTNews Biotech↗ 原文
Pathos AI Signs $2.2B Global Licensing Deal With Alphamab Oncology; Shares Rise
Pathos AI, a clinical-stage company integrating artificial intelligence into oncology drug development, has entered int…
▼ 亏 -1.06%入场 08-04 盘中首笔 @7.933 → 离场 08-05 开盘 @7.895
日 K 取自复盘打分切片 · 蓝点/蓝虚线 = 纸面入场价 · 灰虚线 = 纸面离场 · 持有期红底 = 赚(价格在入场线上方)、绿底 = 亏
💡 交易逻辑授权首付款超营收，限价做多重估
怎么买 限价买入 不高于消息价 +3%、当日有效，不成交作废
怎么卖 止盈 +6%(半仓)/+12%(清仓) · 止损 -6% · 时间止损 5日
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
分时走势
做多 09966.HK 康宁杰瑞制药-B
建仓日早于近 30 天,只有日线图
成交明细 · 纸面
做多 09966.HK 康宁杰瑞制药-B
| 收益状态 | -1.06% 已平仓 |
|---|---|
| 进场成交 | 2026-08-04 · 盘中首笔 · 08-04 11:57 北京 · @7.933 · 成交 1% |
| 离场成交 | 2026-08-05 · 开盘 · @7.895 |
| 毛收益 | -0.48% |
| 成本 | +0.58% |
| 净收益 | -1.06% |
| 计入收益 | -0.01% |
| 建仓日 | 2026-08-04 · 进场不早于新闻时刻 + 2 分钟 |
收益口径 event_time_plus_2min_10min_walk_open_topup_to_next_open_exchange_calendar_fill_model_local_notional_v9 · method_id m8db1cbc8f2d · 截至 2026-10-28 00:08
研究档案
消息传播链
- 港交所披露康宁杰瑞与Pathos AI就JSKN016进行交易，确认授权事件存在；未抓到分钟级披露时点。
- RTTNews转述交易条款：1.25亿美元首付款、最高20.9亿美元里程碑及高个位数至低双位数销售提成。市场反应:报道中称康宁杰瑞股价约7.95港元、涨7.50%。
- 2026-08-04 13:34 HK市场反应Futu非一手行情显示康宁杰瑞制药-B（09966.HK）报7.835港元，较前收7.40港元上涨5.88%，涨幅较媒体报道时略回落。市场反应:盘中仍上涨但未封死，连续交易可成交。
关键理由
- 康宁杰瑞制药-B（09966.HK）获得1.25亿美元不可退还首付款，约9.75亿港元，占当前约75.9亿港元市值约12.9%，对小市值港股Biotech属于可量化现金流重估。
- 公司2025年收入5.66亿元人民币、亏损1.14亿元人民币、现金13.50亿元人民币，本次首付款约8.98亿元人民币，超过全年收入基数并显著延长研发资金 runway。
- 先例深研显示，港股创新药出海授权在首付款较市值显著时通常有正向重估；但股价已盘中上涨，买点需限价而非追高。
主要风险
- 股价盘中已涨5.88%，同类授权先例常见高开冲高后回落，需用限价避免追高。
- 20.9亿美元里程碑高度依赖临床、注册和销售进展，JSKN016仍是临床阶段ADC，不能按全额合同直接估值。
- 高相似先例样本不足以精确锚定5日涨幅，上限主要参考首日强反应而非确定业绩兑现。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 none
内部KB未命中近期足以推翻本次做多方向的监管、业绩下修或JSKN016重大负面信息。
检索:09966.HK 康宁杰瑞 近期 利空 风险 业绩 下调 监管 调查 JSKN016 - 做多前查反向 · 来源 web · 影响 none
公开检索未见近期当事方否认、重大监管调查或交易条款反向修正。
检索:Alphamab Oncology recent negative news lawsuit regulatory investigation 2026
先例如何影响了这次决策
对本次决策的影响:先例支持首轮做多方向，但把买点收紧为盘中限价、将止盈从8%-15%下调到6%-12%，仓位维持small。
方向:高相似样本均指向正向重估，公开反应约+9%至+19%，同一公司JSKN003极端样本首日+54%。
涨幅量级:用高相似且首发锚较干净的09966/9926/02142定量级，保守目标取剩余+6%至+12%，不把09966上次+54%作为本次目标上限。
形态:多条先例显示首日会冲高后回落，尤其Akeso盘中约+40%收+18.7%，当前应保留限价而非市价追涨。
历史先例(按相似度)
- 相似度 8/10 09966 2024-09-29 康宁杰瑞将JSKN003中国内地权益授权给石药，首付款4亿元、总额30.8亿元。 原文 ↗
事件后 +1日 -7.2% · +2日 -9.3% · +3日 +0.8% · +4日 +5.1% · +5日 -1.9%
⚠来源层级不符(声明issuer/实为media) — 该行涨幅别用来定止盈止损
相似度依据:同一公司、同为ADC授权且有明确首付款和里程碑；但该次为中国内地权益且发生在港A医药强势日。
经验:同一公司上次ADC授权在首付款确认后首日大涨，说明市场会把现金流和平台验证快速资本化，但极端涨幅不可线性外推。 - 相似度 8/10 9926 2022-12-06 康方生物将ivonescimab授权给Summit，获5亿美元首付款、最高50亿美元交易额。 原文 ↗
事件后 +1日 +18.8% · +2日 +24.6% · +3日 +31.6% · +4日 +28.9% · +5日 +35.0%
⚠锚前1-2日已异动8.6%>锚定日1.0% — 该行涨幅别用来定止盈止损
相似度依据:港股创新药出海授权、海外公司取得主要市场权益、首付款显著；但Akeso资产更成熟、首付款更大。
经验:大额首付款的出海授权能触发快速重估，但盘中冲高40%后收窄到18.7%，追高需要纪律。 - 相似度 8/10 02142 2026-02-22 和铂医药将HBM4003大中华区外权益授权给Solstice，前期对价逾1.05亿美元、里程碑约11亿美元。 原文 ↗
事件后 +1日 -4.2% · +2日 -5.4% · +3日 -7.0% · +4日 -4.9% · +5日 -7.9%
⚠来源层级不符(声明issuer/实为media) — 该行涨幅别用来定止盈止损
相似度依据:港股小市值Biotech、临床阶段肿瘤资产出海授权、前期对价约1亿美元，和当前首付款量级接近。
经验:小市值港股Biotech拿到过亿美元前期对价时首日常有约10%级别重估，适合小仓限价参与而非重仓。 - 相似度 7/10 03692 2023-12-20 翰森制药将HS-20093大中华区外权益授权给GSK，获1.85亿美元首付款、最高15.25亿美元里程碑。 原文 ↗
事件后 +1日 -11.9% · +2日 -6.8% · +3日 -4.7% · +4日 -1.6% · +5日 +5.1%
相似度依据:港股药企、ADC出海、GSK获大中华区外权益，条款结构相似；但翰森已有商业化收入且市值更大。
经验:大市值商业化药企的同类ADC出海更多是确认平台价值，股价弹性通常弱于小市值Biotech。 - 相似度 7/10 0013 2023-01-23 和黄医药将呋喹替尼中国外权益授权给武田，获4亿美元首付款、最高11.3亿美元总额。 原文 ↗
事件后 +1日 +0.8% · +2日 -6.3% · +3日 -8.6% · +4日 -3.5% · +5日 +0.0%
⚠来源层级不符(声明issuer/实为media) — 该行涨幅别用来定止盈止损
相似度依据:港股创新药对外授权且有4亿美元首付款；但和黄医药资产已近上市、公司规模更大，现金弹性不同。
经验:成熟资产的大额授权强化盈利路径，但大公司弹性不如小盘临床阶段公司，不能直接套用涨幅。 - 相似度 6/10 01801 2026-05-28 信达生物与辉瑞就12个肿瘤项目达成全球合作，获6.5亿美元首付款及最高98.5亿美元里程碑。 原文 ↗
事件后 +1日 +11.4% · +2日 +8.1% · +3日 +5.3% · +4日 +2.7% · +5日 +2.1%
相似度依据:港股创新药与辉瑞达成肿瘤管线授权合作，首付款6.5亿美元；但项目组合更大、信达市值和商业化能力强于当前。
经验:组合型大额出海授权能推升港股Biotech风险偏好，首日约10%反应可作为当前限价后目标区间参考。 - 相似度 6/10 688221 2026-02-24 前沿生物两款siRNA全球授权给GSK，获4000万美元首付款、1300万美元近期里程碑及最高9.5亿美元后续里程碑。 原文 ↗
事件后 +1日 -4.1% · +2日 -12.3% · +3日 -14.2% · +4日 -20.2% · +5日 -25.1%
⚠来源层级不符(声明issuer/实为media) — 该行涨幅别用来定止盈止损
相似度依据:A股早期管线全球授权给GSK，现金流逻辑相似；但siRNA品类、A股涨跌停机制和市场相位不同。
经验:早期项目即便存在里程碑不确定性，首付款到账和国际药企背书仍会触发短线交易，但A股容易冲高回落。 - 相似度 5/10 600276 2026-05-12 恒瑞医药与BMS达成13个项目合作，BMS支付6亿美元首付款及最高约152亿美元潜在总额。 原文 ↗
事件后 +1日 -0.5% · +2日 -3.2% · +3日 -3.8% · +4日 -6.6% · +5日 -8.1%
⚠来源层级不符(声明issuer/实为media) — 该行涨幅别用来定止盈止损
相似度依据:中国药企与跨国药企多项目授权合作，首付款巨大；但恒瑞是超大市值、项目组合型合作，与09966小盘单品种授权差异较大。
经验:超大市值药企也能因确定首付款和全球背书上涨，但弹性被市值稀释，更多验证行业风险偏好。
工具调用 · 历史记录,结果未知(5 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
- search_case_library · 结果未知
- validate_order · 结果未知
原文全文
展开原文 · 2,731 字
Pathos AI, a clinical-stage company integrating artificial intelligence into oncology drug development, has entered into a global licensing agreement with Alphamab Oncology (9966.HK) for JSKN016, a first-in-class bispecific antibody-drug conjugate targeting TROP2 and HER3.
The program joins Pocenbrodib, Pathos's internally developed CBP/p300 bromodomain inhibitor currently in a Phase 1b/2a trial for metastatic castration-resistant prostate cancer (mCRPC).
JSKN016 was independently developed by Alphamab and will now be advanced globally by Pathos, excluding the Chinese Mainland, Hong Kong, Macau, and Taiwan, where Alphamab retains exclusive rights. The therapy is developed for solid tumors and is also under evaluation across four additional indications, including lung, breast, gastric, and colorectal cancers, broadening its potential reach in oncology.
Under the agreement, Alphamab will receive a non-refundable upfront payment of $125 million, milestone payments totaling up to $2.09 billion, and tiered royalties ranging from high single-digit to low double-digit percentages based on annual net sales in licensed territories.
Pathos identified JSKN016 through its proprietary AI-driven Foundry platform, which uses thousands of AI agents to analyze biological, clinical, and real-world data at scale. Foundry has already advanced three other clinical-stage programs, with JSKN016 becoming the fourth in its pipeline.
Pathos CEO Iker Huerga described JSKN016 as a next-generation therapy with potential to address unmet needs across solid tumors, emphasizing the collaboration as part of a broader commitment to differentiated cancer treatments. Alphamab highlighted the partnership as a way to accelerate global clinical development and deliver innovative therapies to patients worldwide.
This agreement positions Pathos AI to expand its oncology pipeline with a novel bispecific ADC, while Alphamab secures significant financial milestones and retains rights in its home markets.
Shares of Alphamab Oncology (9966.HK) have traded between HKD 6.23 and HKD 15.75 over the past year. The stock is currently trading at HKD 7.95, up 7.50%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 01, 2026 02:10 ET Major central banks, led by the U.S. Federal Reserve, and preliminary estimates of second quarter economic growth dominated the economics news flow this week. In the U.S., the Federal Reserve announced its latest policy decision and early estimates of second quarter growth and monthly inflation data were also released. In Europe, the interest rate decision from the Bank of England was in focus. Similarly, the Bank of Japan was in the limelight in Asia for its policy announcement.
The program joins Pocenbrodib, Pathos's internally developed CBP/p300 bromodomain inhibitor currently in a Phase 1b/2a trial for metastatic castration-resistant prostate cancer (mCRPC).
JSKN016 was independently developed by Alphamab and will now be advanced globally by Pathos, excluding the Chinese Mainland, Hong Kong, Macau, and Taiwan, where Alphamab retains exclusive rights. The therapy is developed for solid tumors and is also under evaluation across four additional indications, including lung, breast, gastric, and colorectal cancers, broadening its potential reach in oncology.
Under the agreement, Alphamab will receive a non-refundable upfront payment of $125 million, milestone payments totaling up to $2.09 billion, and tiered royalties ranging from high single-digit to low double-digit percentages based on annual net sales in licensed territories.
Pathos identified JSKN016 through its proprietary AI-driven Foundry platform, which uses thousands of AI agents to analyze biological, clinical, and real-world data at scale. Foundry has already advanced three other clinical-stage programs, with JSKN016 becoming the fourth in its pipeline.
Pathos CEO Iker Huerga described JSKN016 as a next-generation therapy with potential to address unmet needs across solid tumors, emphasizing the collaboration as part of a broader commitment to differentiated cancer treatments. Alphamab highlighted the partnership as a way to accelerate global clinical development and deliver innovative therapies to patients worldwide.
This agreement positions Pathos AI to expand its oncology pipeline with a novel bispecific ADC, while Alphamab secures significant financial milestones and retains rights in its home markets.
Shares of Alphamab Oncology (9966.HK) have traded between HKD 6.23 and HKD 15.75 over the past year. The stock is currently trading at HKD 7.95, up 7.50%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 01, 2026 02:10 ET Major central banks, led by the U.S. Federal Reserve, and preliminary estimates of second quarter economic growth dominated the economics news flow this week. In the U.S., the Federal Reserve announced its latest policy decision and early estimates of second quarter growth and monthly inflation data were also released. In Europe, the interest rate decision from the Bank of England was in focus. Similarly, the Bank of Japan was in the limelight in Asia for its policy announcement.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。